ALP Life Sciences was founded to conduct research in the emerging and exciting field of Applied Lipid Polymorphism (ALP), which is simply the use of therapeutic doses of lipids to trigger the remodeling of lipid balances in the human body. ALP is pursuing a promising novel therapy and diagnostics for fatty liver disease, the Nanoveson project. Fatty liver disease involves an imbalance of lipid stores and metabolism in the liver. In short, it involves too much fat stored in the liver.
Fatty liver disease is often known as non-alcoholic fatty liver disease (NAFLD), which often progresses to non-alcoholic steatohepatitis (NASH), which progresses to cirrhosis. These diseases represent an epidemic in both the developed and emerging world. The mounting research indicates that excessive dietary intake of Omega-6 and reduced intake of Omega-3 fatty acids increases the AA/EPA ratio. This appears to play a role in the development of fatty liver disease, and many related inflammatory diseases. ALP will keep registered physicians and health care providers updated on ALP research progress on fatty liver disease. [View Research]